Paula Fernstrom
Nexium Global Product Director, AstraZeneca
18
0
18
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+1 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (18)
Showing 10 of 18 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Professor Chris Hawkey
Queens Medical Centre
Shared therapeutic areas:
Worked with same sponsors:
Saleh K Saleh, MD
Minia University
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Ali MA Ismail, lecturer
Cairo University
Shared therapeutic areas:
Hagop Youssoufian, MD
Verastem, Inc.
Shared therapeutic areas:
Toshimitsu Tokimoto
Astrazeneca KK
Shared therapeutic areas:
Worked with same sponsors:
Jacqueline Pongracic, MD
Ann & Robert H Lurie Children's Hospital of Chicago
Shared therapeutic areas:
Ganesh Raghu, MD
University of Washington
Shared therapeutic areas:
Craig LaForce, MD
North Carolina Clinical Research
Shared therapeutic areas:
Worked with same sponsors:
Suman Sheraz, PhD*
Riphah International University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (18)
Showing 18 of 18 trials
A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv
A Multicenter, Randomized, Double-Blind Parallel-Group, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg Once Daily to Placebo qd for the Resolution of Upper Abdominal Pain in Patients With Symptomatic Gastroesophageal Reflux Disease (sGERD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)
Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only
A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued
Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
Quality of Life Validation in Laryngitis
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
All 18 trials loaded